Is COPD a Risk Factor for Cardiovascular Disease?
Is Chronic Obstructive Pulmonary Disease a Risk Factor for Cardiovascular Disease?
研究概览
地位
条件
详细说明
Patients with chronic obstructive pulmonary disease (COPD) suffer from significant cardiovascular morbidity and mortality. Coronary artery disease has often been linked causally to COPD, but the exact pathophysiological mechanisms underpinning this association remain speculative. A retrospective case-control study matching COPD patients and controls one to one for smoking history and conventional cardiovascular risk factors will be performed to study the association between COPD and cardiovascular outcomes. Filling in this knowledge gap may contribute to the understanding of the interplay between COPD and cardiovascular disease.
The objective of this retrospective case-control study is to determine whether COPD might be a risk factor for coronary atherosclerosis, impaired left ventricular ejection fraction, and major adverse cardiovascular events independent of conventional cardiovascular risk factors.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Zurich、瑞士、8091
- University Hospital Zurich, Pulmonary Division
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- SPECT-CT imaging due to preoperative assessment between 01.01.2007 and 31.07.2013.
- Coronary artery calcium score and left ventricular ejection fraction data available.
- History of smoking (smoker or ex-smoker).
- COPD group: Documented chronic obstructive pulmonary disease (post-bronchodilator FEV1/FVC < 0.7).
- Control group: Exclusion of chronic obstructive pulmonary disease (post-bronchodilator FEV1/FVC > 0.7).
Exclusion Criteria:
- Known coronary artery disease or coronary symptoms (angina pectoris) at the time of the SPECT-CT investigation.
- Known congenital or structural heart disease.
- Previous heart transplantation.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Chronic obstructive pulmonary disease
Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) < 0.7).
|
|
Control
Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) > 0.7).
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Coronary calcium score in cardiac computed tomography
大体时间:Up to one month
|
Retrospective assessment of SPECT-CT imaging data at the University Hospital Zurich.
|
Up to one month
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Left ventricular ejection fraction in single-photon emission computed tomography
大体时间:Up to one month
|
Retrospective assessment of SPECT-CT imaging data at the University Hospital Zurich.
|
Up to one month
|
|
Major adverse cardiovascular events
大体时间:Up to three months
|
Follow-up via telephone interview for major adverse cardiovascular events.
|
Up to three months
|
合作者和调查者
调查人员
- 首席研究员:Malcolm Kohler, MD, Prof、University of Zurich
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.